Low-dose CT screening could prevent ~12,000 lung cancer deaths annually

This article originally appeared here.
Low-Dose CT Screening Could Avert ~12,000 Lung CA Deaths
Low-Dose CT Screening Could Avert ~12,000 Lung CA Deaths

(HealthDay News) -- Adoption of low-dose computed tomography (LDCT) screening regimens, as outlined in the National Lung Screening Trial (NLST), could potentially prevent more than 12,000 lung cancer deaths in the United States each year, according to research published online Feb. 25 in Cancer.

Jiemin Ma, Ph.D., M.H.S., from the American Cancer Society in Atlanta, and colleagues estimated the annual number of lung cancer deaths that could be averted by LDCT screening, assuming implementation of the screening regimens adopted in the NLST. The estimates were based on the screening effect, the U.S. population size, screening eligibility prevalence, and the lung-cancer mortality rate among the population eligible for screening.

The researchers found that, in 2010, approximately 8.6 million Americans (5.2 million men and 3.4 million women) were eligible for lung cancer screening. Full implementation of the screening regimen adopted in the NLST would potentially avert 12,250 lung cancer deaths each year (8,990 in men and 3,260 in women).

"We estimated that approximately 12,000 lung cancer deaths could potentially be averted per year through the full implementation of LDCT screening among eligible heavy smokers in the United States, based on our current knowledge of screening," the authors write. "Further studies are needed to estimate the number of avertable lung cancer deaths and the cost-effectiveness of LDCT screening under different scenarios of risk, various screening frequencies, and various screening uptake rates."

Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)

Loading links....
You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs